Video

Dr. Sekeres on the Need for Novel Combinations in Higher-Risk MDS/CMML and Low-Blast AML

Mikkael A. Sekeres, MD, discusses the need for novel combinations in higher-risk myelodysplastic syndrome (MDS)/chronic myelomonocytic leukemia (CMML) and low-blast acute myelogenous leukemia (LB AML).

Mikkael A. Sekeres, MD, professor of medicine, director, Leukemia Program, Cleveland Clinic Taussig Cancer Institute, discusses the need for novel combinations in higher-risk myelodysplastic syndrome (MDS)/chronic myelomonocytic leukemia (CMML) and low-blast acute myelogenous leukemia (LB AML).

Patients with higher-risk MDS/CMML and oligoblastic AML (less than 30% blasts) typically receive 1 of 2 treatment regimens: intensive induction chemotherapy or less intensive treatment with a hypomethylating agent. High-intensity treatment has a high treatment-related mortality rate and is cumbersome for older patients with comorbidities, says Sekeres, and less intensive treatment with azacitidine alone results in relatively low and short-lived responses.

As such, investigators launched a phase 2 trial (NCT02610777) which evaluated the addition of pevonedistat, the first and only small-molecule inhibitor of the NEDD8-activating enzyme, to azacitidine in patients with higher-risk MDS/CMML and LB AML. The results were presented in an oral presentation at the 2020 ASCO Virtual Scientific Program.

Related Videos
Paolo Tarantino, MD
Aditya Bardia, MD, MPH, FASCO
Giuseppe Curigliano, MD, PhD, director, Early Drug Development Division, co-chair, Experimental Therapeutics Program, the European Institute of Oncology
Mina Lobbous, MD, MPH
Noa Biran, MD
Andrew Hantel, MD
Peter Forsyth, MD
Jakub Svoboda, MD
Joaquim Bellmunt, MD, PhD
María-Victoria Mateos, MD, PhD